Oncoinvent ASA: First day of trading on Euronext Growth Oslo and publication of information document

13 Dec 2024 06:47 CET

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR
ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES
DESCRIBED HEREIN.

Oslo, 13 December 2024

Reference is made to the stock exchange announcement published by Oncoinvent ASA
("Oncoinvent" or the "Company") on 11 December 2024 regarding the registration
of the share capital increase pertaining to a private placement of in total 65
million new shares (the "Offer Shares"), each with a nominal value of 0.10, at a
subscription price of NOK 2 per Offer Share, resulting in gross proceeds to the
Company of 130 million (the "Private Placement"). All Offer Shares have now been
issued in the Norwegian Central Securities Depository. Delivery of Offer Shares
to investors in the Private Placement will take place on a delivery versus
payment basis on or about 13 December 2024.

The first day of trading of the Company's shares on Euronext Growth Oslo is
today, 13 December 2024, under the ticker "ONCIN". The Company has prepared an
information document solely for the purpose of the admission to trading, which
is attached to this announcement and can also be found on the Company’s website:
https://www.oncoinvent.com/.

“Oncoinvent is thrilled to join Euronext Growth, a milestone that underscores
our commitment to advancing innovative cancer therapies. This listing will
enhance our visibility, attract new investors, and provide the financial
flexibility and stability needed to accelerate our clinical development program
to data in 2025 and 2026. We look forward to leveraging this platform to drive
growth, not only of Oncoinvent but eventually also of the Oslo
radiopharmaceutical ecosystem” says Øystein Soug, CEO.

Advisors:
Carnegie AS and DNB Markets, a part of DNB Bank ASA acted as joint bookrunners
and managers in connection with the Private Placement, and as listing advisors
to the Company in connection with its admission to trading on Euronext Growth
Oslo (the "Managers").

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.
Advokatfirmaet Wiersholm AS is acting as legal advisor to the Managers.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing
innovative treatments for solid cancers. The technology platform is focused on
the use of alpha-emitting radionuclides to deliver powerful radiation directly
to cancer cells. The Company’s lead product candidate, Radspherin®, is being
advanced through clinical development by a team with experience from all stages
of radiopharmaceutical development. Internal manufacturing and supply chain
capabilities have been established, which now have the capacity to supply
Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com


Important information
The release is not for publication or distribution, in whole or in part directly
or indirectly, in or into Australia, Canada, Japan or the United States
(including its territories and possessions, any state of the United States and
the District of Columbia). This release is an announcement issued pursuant to
legal information obligations. It is issued for information purposes only, and
does not constitute or form part of any offer or solicitation to purchase or
subscribe for securities, in the United States or in any other jurisdiction. The
securities mentioned herein have not been, and will not be, registered under the
United States Securities Act of 1933, as amended (the “US Securities Act”). The
securities may not be offered or sold in the United States except pursuant to an
exemption from the registration requirements of the US Securities Act.

The Company does not intend to register any portion of the offering of the
securities in the United States or to conduct a public offering of the
securities in the United States. Copies of this announcement are not being made
and may not be distributed or sent into Australia, Canada, Japan or the United
States.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 on prospectuses to be published when securities are offered to the
public or admitted to trading on a regulated market, and repealing Directive
2003/71/EC (as amended) as implemented in any Member State.

The issue, subscription or purchase of shares in the Company is subject to
specific legal or regulatory restrictions in certain jurisdictions. Neither the
Company nor the Managers assume any responsibility in the event there is a
violation by any person of such restrictions. The distribution of this release
may in certain jurisdictions be restricted by law. Persons into whose possession
this release comes should inform themselves about and observe any such
restrictions. Any failure to comply with these restrictions may constitute a
violation of the securities laws of any such jurisdiction. The Managers are
acting for the Company and no one else in connection with the Private Placement
and will not be responsible to anyone other than the Company providing the
protections afforded to their respective clients or for providing advice in
relation to the Private Placement and/or any other matter referred to in this
release.

Forward-looking statements: This release and any materials distributed in
connection with this release may contain certain forward-looking statements. By
their nature, forward-looking statements involve risk and uncertainty because
they reflect the Company’s current expectations and assumptions as to future
events and circumstances that may not prove accurate. A number of material
factors could cause actual results and developments to differ materially from
those expressed or implied by these forward-looking statements.

More information:
Access the news on Oslo Bors NewsWeb site

634620_Oncoinvent ASA - Information Document (Final 12.12.2024).pdf